



LABORATORY REPORT



Name : Mrs. NEERAJ SAINI	Sex/Age : Female / 37 Years	Case ID : 30908001148
Ref. By : MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40	Dis. At :	Pt. ID :
Bill. Loc. : SPH OPD		Pt. Loc. :
Reg Date and Time : 23-Sep-2023 09:21	Sample Type : Whole Blood EDTA	Mobile No. :
Sample Date and Time : 23-Sep-2023 09:21	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 23-Sep-2023 11:08	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF. INTERVAL	REMARKS
------	---------	------	--------------------------	---------

HAEMOGRAM REPORT

HB AND INDICES

Haemoglobin	L 11.6	G%	12.0 - 15.0
RBC (Electrical Impedance)	4.29	millions/cumm	3.80 - 4.80
PCV(Calc)	37.49	%	36.00 - 46.00
MCV (RBC histogram)	87.4	fL	83.00 - 101.00
MCH (Calc)	L 26.9	pg	27.00 - 32.00
MCHC (Calc)	L 30.8	gm/dL	31.50 - 34.50
RDW (RBC histogram)	14.30	%	11.00 - 16.00

TOTAL AND DIFFERENTIAL WBC COUNT

		UNIT	EXPECTED VALUES	[Abs]	EXPECTED VALUES
Total WBC Count	7610	/μL	4000.00 - 10000.00		
Neutrophil	[%] 61	%	40.00 - 70.00	4642	/μL 2000.00 - 7000.00
Lymphocyte	29	%	20.00 - 40.00	2207	/μL 1000.00 - 3000.00
Eosinophil	06	%	1.00 - 6.00	457	/μL 20.00 - 500.00
Monocytes	04	%	2.00 - 10.00	304	/μL 200.00 - 1000.00
Basophil	0.0	%	0.00 - 2.00	0	/μL 0.00 - 100.00

PLATELET COUNT

Platelet Count	259000	/μL	150000.00 - 410000.00
MPV	10.50	fL	6.5 - 12
PDW	H 16.1		8 - 13

Method:

TLC-SF cube technology(Flow Cytometry+ fluorescence),
DC by microscopy,
Platelet count by electrical impedance+/-SF cube technology

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist
GMC No. G-11309
Page 1 of 9

Printed On : 05-Dec-2023 11:17



LABORATORY REPORT



Name : Mrs. NEERAJ SAINI	Sex/Age : Female / 37 Years	Case ID : 30908001148
Ref. By : MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40	Dis. At :	Pt. ID :
Bill. Loc. : SPH OPD		Pt. Loc. :
Reg Date and Time : 23-Sep-2023 09:21	Sample Type : Whole Blood EDTA	Mobile No. :
Sample Date and Time : 23-Sep-2023 09:21	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 23-Sep-2023 14:59	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

HAEMATOLOGY INVESTIGATIONS

ESR H 25 mm after 1hr 3 - 20
Westergren Method

BLOOD GROUP AND RH TYPING (Erythrocyte Magnetized Technology) (Both Forward and Reverse Group)

ABO Type O
Rh Type POSITIVE

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah
 Consultant Pathologist
 GMC No. G-11309
 Page 2 of 9

Printed On : 05-Dec-2023 11:17



LABORATORY REPORT



Name : **Mrs. NEERAJ SAINI** Sex/Age : **Female / 37 Years** Case ID : **30908001148**
 Ref. By : **MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40** Dis. At : Pt. ID :
 Bill. Loc. : **SPH OPD** Pt. Loc. :

Reg Date and Time : 23-Sep-2023 09:21 Sample Type : **Plasma Fluoride F, Plasma Fluoride PP, Whole Blood EDTA** Mobile No. :
 Sample Date and Time : 23-Sep-2023 09:21 Sample Coll. By : **non** Ref Id1 :
 Report Date and Time : 23-Sep-2023 12:24 Acc. Remarks : Ref Id2 :
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

Plasma Glucose - F **97.55** mg/dL 70 - 100 FUS: NIL
Photometric, Hexokinase
Plasma Glucose - PP **124.94** mg/dL 70 - 140 PPUS: NIL
Photometric, Hexokinase

Glycated Haemoglobin Estimation

HbA1C **5.0** % of total Hb <5.7: Normal
Immunoturbidimetric 5.7-6.4: Prediabetes
 >=6.5: Diabetes
Estimated Avg Glucose (3 Mths) **96.80** mg/dL Not available
Calculated

Please Note change in reference range as per ADA 2021 guidelines.

Interpretation :

HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.
 Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.
 Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.
 Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA.
 In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.
 The A1c target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist
 GMC No. G-11309
 Page 3 of 9

Printed On : 05-Dec-2023 11:17



LABORATORY REPORT



Name : **Mrs. NEERAJ SAINI** Sex/Age : **Female / 37 Years** Case ID : **30908001148**
 Ref. By : **MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40** Dis. At : Pt. ID :
 Bill. Loc. : **SPH OPD** Pt. Loc. :

Reg Date and Time : 23-Sep-2023 09:21 Sample Type : Serum Mobile No. :
 Sample Date and Time : 23-Sep-2023 09:21 Sample Coll. By : non Ref Id1 :
 Report Date and Time : 23-Sep-2023 11:09 Acc. Remarks : Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

BIOCHEMICAL INVESTIGATIONS

Lipid Profile

Cholesterol <i>Colorimetric, CHOD-POD</i>	H	266.85	mg/dL	110 - 200
HDL Cholesterol		52.6	mg/dL	40 - 60
Triglyceride <i>GPO-POD</i>		124.71	mg/dL	40 - 200
VLDL <i>Calculated</i>		24.94	mg/dL	10 - 40
Chol/HDL <i>Calculated</i>	H	5.07		0 - 4.1
LDL Cholesterol <i>Calculated</i>	H	189.31	mg/dL	0.00 - 100.00

NEW ATP III GUIDELINES (MAY 2001), MODIFICATION OF NCEP

LDL CHOLESTEROL	CHOLESTEROL	HDL CHOLESTEROL	TRIGLYCERIDES
Optimal <100	Desirable <200	Low <40	Normal <150
Near Optimal 100-129	Border Line 200-239	High >60	Border High 150-199
Borderline 130-159	High >240	-	High 200-499
High 160-189	-	-	-

- LDL Cholesterol level is primary goal for treatment and varies with risk category and assesment
- For LDL Cholesterol level Please consider direct LDL value
Risk assessment from HDL and Triglyceride has been revised. Also LDL goals have changed.
- Detail test interpreation available from the lab
- All tests are done according to NCEP guidelines and with FDA approved kits.
- LDL Cholesterol level is primary goal for treatment and varies with risk category and assesment

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist
 GMC No. G-11309
 Page 4 of 9

Printed On : 05-Dec-2023 11:17



LABORATORY REPORT



Name : Mrs. NEERAJ SAINI	Sex/Age : Female / 37 Years	Case ID : 30908001148
Ref. By : MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40	Dis. At :	Pt. ID :
Bill. Loc. : SPH OPD		Pt. Loc. :
Reg Date and Time : 23-Sep-2023 09:21	Sample Type : Serum	Mobile No. :
Sample Date and Time : 23-Sep-2023 09:21	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 23-Sep-2023 12:25	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

BIOCHEMICAL INVESTIGATIONS

Liver Function Test

S.G.P.T. <i>IFCC</i>	H	64.53	U/L	0 - 59
S.G.O.T. <i>IFCC</i>		53.30	U/L	
Alkaline Phosphatase <i>Modified IFCC method</i>		94.67	U/L	40 - 150
Proteins (Total) <i>Colorimetric, Biuret</i>		6.46	gm/dL	6.40 - 8.30
Albumin <i>Bromo Cresol Green</i>		4.72	g/dL	3.4 - 5.0
Globulin <i>Calculated</i>	L	1.74	gm/dL	2 - 4.1
A/G Ratio <i>Calculated</i>	H	2.7		1.0 - 2.1
Bilirubin Total <i>Photometry</i>		0.88	mg/dL	0.3 - 1.2
Bilirubin Conjugated <i>Diazotization reaction</i>		0.23	mg/dL	0 - 0.50
Bilirubin Unconjugated <i>Calculated</i>		0.65	mg/dL	0 - 0.8

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist

GMC No. G-11309

Page 5 of 9

Printed On : 05-Dec-2023 11:17



LABORATORY REPORT



Name : **Mrs. NEERAJ SAINI** Sex/Age : **Female / 37 Years** Case ID : **30908001148**
 Ref. By : **MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40** Dis. At : Pt. ID :
 Bill. Loc. : **SPH OPD** Pt. Loc. :

Reg Date and Time : 23-Sep-2023 09:21	Sample Type : Serum	Mobile No. :
Sample Date and Time : 23-Sep-2023 09:21	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 23-Sep-2023 11:21	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
BUN (Blood Urea Nitrogen) <i>GLDH</i>	8.3	mg/dL	7.00 - 18.70	
Creatinine <i>Jaffe compensated</i>	0.58	mg/dL	0.55 - 1.02	
Uric Acid <i>Uricase-Peroxidase method</i>	H 6.60	mg/dL	2.6 - 6.2	

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist
 GMC No. G-11309
 Page 6 of 9

Printed On : 05-Dec-2023 11:17



LABORATORY REPORT



Name : **Mrs. NEERAJ SAINI** Sex/Age : **Female / 37 Years** Case ID : **30908001148**
 Ref. By : **MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40** Dis. At : Pt. ID :
 Bill. Loc. : **SPH OPD** Pt. Loc. :

Reg Date and Time : 23-Sep-2023 09:21	Sample Type : Serum	Mobile No. :
Sample Date and Time : 23-Sep-2023 09:21	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 23-Sep-2023 12:24	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

BIOCHEMICAL INVESTIGATIONS

Thyroid Function Test

Triiodothyronine (T3) <i>CMIA</i>	1.52	ng/mL	0.70 - 2.04
Thyroxine (T4) <i>CMIA</i>	10.05	µg/dL	5.5 - 11.0
TSH <i>CMIA</i>	3.46	µIU/mL	0.4 - 4.2

INTERPRETATIONS

Useful for Monitoring patients on thyroid replacement therapy, Confirmation of thyroid-stimulating hormone (TSH) suppression in thyroid cancer patients on thyroxine therapy, for Prediction of thyrotropin-releasing hormone-stimulated TSH response, as An aid in the diagnosis of primary hyperthyroidism, for Differential diagnosis of hypothyroidism.
 The ability to quantitate circulating levels of thyroid-stimulating hormone (TSH) is important in evaluating thyroid function. It is especially useful in the differential diagnosis of primary (thyroid) from secondary (pituitary) and tertiary (hypothalamus) hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low or normal. Concentrations of 5.1 mIU/ml to 7.0 mIU/ml are considered borderline hypothyroid

CAUTIONS

Sick, hospitalized patients may have falsely low or transiently elevated thyroid stimulating hormone.
 Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedure, may have circulating antianimal antibodies present. These antibodies may interfere with the assay reagents to produce unreliable results.

TSH ref range in Pregnancy	Reference range (microu/ml)
First trimester	0.24 - 2.00
Second trimester	0.43-2.2
Third trimester	0.8-2.5

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist
 GMC No. G-11309
 Page 7 of 9

Printed On : 05-Dec-2023 11:17



LABORATORY REPORT



Name : **Mrs. NEERAJ SAINI** Sex/Age : **Female / 37 Years** Case ID : **30908001148**
 Ref. By : **MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40** Dis. At : Pt. ID :
 Bill. Loc. : **SPH OPD** Pt. Loc. :

Reg Date and Time : 23-Sep-2023 09:21	Sample Type : Spot Urine	Mobile No. :
Sample Date and Time : 23-Sep-2023 09:21	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 23-Sep-2023 14:25	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

URINE EXAMINATION (STRIP METHOD AND FLOWCYTOMETRY)

Physical examination

Colour Pale yellow
Transparency Clear

Chemical Examination By Sysmex UC-3500

Sp.Gravity	1.015		1.003 - 1.035
pH	6.0		4.6 - 8
Leucocytes (ESTERASE)	Negative		Negative
Protein	Negative		Negative
Glucose	Negative		Negative
Ketone Bodies Urine	Negative		Negative
Urobilinogen	Normal		Negative
Bilirubin	Negative		Negative
Blood	Negative		Negative
Nitrite	Negative		Negative

Flowcytometric Examination By Sysmex UF-5000

Leucocyte	Occasional	/HPF	Nil
Red Blood Cell	Nil	/HPF	Nil
Epithelial Cell	1-2	/HPF	Present(+)
Bacteria	Nil	/ul	Nil
Yeast	Nil	/ul	Nil
Cast	Nil	/LPF	Nil
Crystals	Nil	/HPF	Nil

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist
 GMC No. G-11309
 Page 8 of 9

Printed On : 05-Dec-2023 11:17



LABORATORY REPORT



Name : **Mrs. NEERAJ SAINI** Sex/Age : **Female / 37 Years** Case ID : **30908001148**

Ref. By : **MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE ABOVE 40** Dis. At : Pt. ID :

Bill. Loc. : **SPH OPD** Pt. Loc. :

Reg Date and Time : **23-Sep-2023 09:21** Sample Type : **Spot Urine** Mobile No. :

Sample Date and Time : **23-Sep-2023 09:21** Sample Coll. By : **non** Ref Id1 :

Report Date and Time : **23-Sep-2023 14:25** Acc. Remarks : Ref Id2 :

Parameter	Unit	Expected value	Result/Notations				
			Trace	+	++	+++	++++
pH	-	4.6-8.0					
SG	-	1.003-1.035					
Protein	mg/dL	Negative (<10)	10	25	75	150	500
Glucose	mg/dL	Negative (<30)	30	50	100	300	1000
Bilirubin	mg/dL	Negative (0.2)	0.2	1	3	6	-
Ketone	mg/dL	Negative (<5)	5	15	50	150	-
Urobilinogen	mg/dL	Negative (<1)	1	4	8	12	-

Parameter	Unit	Expected value	Result/Notifications				
			Trace	+	++	+++	++++
Leukocytes (Strip)	/micro L	Negative (<10)	10	25	100	500	-
Nitrite(Strip)	-	Negative	-	-	-	-	-
Erythrocytes(Strip)	/micro L	Negative (<5)	10	25	50	150	250
Pus cells (Microscopic)	/hpf	<5	-	-	-	-	-
Red blood cells(Microscopic)	/hpf	<2	-	-	-	-	-
Cast (Microscopic)	/lpf	<2	-	-	-	-	-

----- End Of Report -----

For test performed on specimens received or collected from non-NSRL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. NSRL will be responsible Only for the analytical part of test carried out. All other responsibility will be of referring Laboratory.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist

GMC No. G-11309

Page 9 of 9

Printed On : 05-Dec-2023 11:17